NCT05787327

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

Assessing the Efficacy and Safety of Yinqiaosan-Maxingganshitang in the Treatment of the Major Symptoms of Mild and Moderate COVID-19 by Telemedicine - a Randomized, Double-blind, Placebo-controlled Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19 patients by telemedicine.

Detailed description

Subjects who are diagnosed with COVID-19 by RATs or PCR tests and fulfilled the eligibility criteria will receive a maximum of 14 days of treatment with Yinqiaosan-Maxingganshitang (with or without specified additions) or placebo and will be followed up on day 7, 14 and 35 after receiving medication (day 0).

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Chinese Herb	Yinqiaosan-Maxingganshitang granules
DIAGNOSTIC_TEST	Placebo	Placebo

Timeline

• Start date: 2023-05-25
• Primary completion: 2024-04-30
• Completion: 2024-09-30
• First posted: 2023-03-28
• Last updated: 2023-07-07

Locations

1 site across 1 country: Hong Kong